ADOCIA Announces Oral Presentations on AdoShell® and BioChaperone® at EASD, ESB and PODD 2025 Annual Meetings

About this update from Adocia Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/63beec58139074dea23252e700af3063"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I3sMCuVqTOcquD0ec4rrhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/63beec58139074dea23252e700af3063","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RLfP2TbB6ilpuKXdIKRhGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/63beec58139074dea23252e700af3063","width":1200,"height":485}},"lazy":false},{"type":"text","content":"LYON, France, September 03, 2025--(BUSINESS WIRE)--Regulatory News:","length":67,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announces oral presentations highlighting the latest preclinical results obtained on its innovative technological platform AdoShell® at EASD and ESB 2025 annual meetings. Adocia will also present at the next PODD 2025 its latest preclinical results on the BioChaperone® platform.","length":518,"tagName":"p"},{"type":"text","content":"AdoShell®","length":9,"tagName":"p"},{"type":"text","content":"The innovative AdoShell® technology platform is designed to implant human insulin-secreting cells from either deceased donors (islets of Langherans) or stem cells to provide a cure for Type 1 diabetes without the need for immunosuppression. Oral presentations at EASD et ESB will highlight the latest AdoShell® preclinical results1:","length":332,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successful scale up from animal to human device for First-In-Human study","length":72,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In vitro and in vivo maturation after encapsulation of immature stem cell-derived islets in AdoShell®","length":101,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sustained long-term in vivo function and efficacy of stem cell-derived islets encapsulated in AdoShell®","length":10...

More updates from Adocia Sa